Vilzemetkib

It's only fair to share...

Vilzemetkib

CAS 1363402-44-1

MF C36H36F2N4O5 MW 642.7 g/mol

1-N‘-[4-[7-[[1-(cyclopentylamino)cyclopropyl]methoxy]-6-methoxyquinolin-4-yl]oxy-3-fluorophenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

hepatocyte growth factor receptor inhibitor, antineoplastic, AL 2846, FJ4Y6XP24Y

Vilzemetkib (also known as AL2846) is an investigational, orally active small-molecule drug that acts as a potent inhibitor of the c-Met receptor tyrosine kinase, a protein often overexpressed in cancers, aiming to block tumor growth, survival, and spread by disrupting key cellular signals. It’s being studied in clinical trials, often in combination with other agents like TQB2450 (a PD-L1 inhibitor), for advanced cancers such as esophageal and liver cancer, showing promise in immunotherapy-resistant patients.

How it Works:

Targets c-Met: Vilzemetkib binds to the c-Met protein, preventing its phosphorylation (activation).
Blocks Signaling: This action disrupts downstream pathways crucial for cancer cell proliferation, survival, invasion, metastasis, and new blood vessel formation (angiogenesis).

Development & Use:

Developer: Developed by Advenchen Laboratories.
Status: Investigational drug, currently in clinical trials.
Research Focus: Studied for cancers like esophageal squamous cell carcinoma (ESCC) and hepatocellular carcinoma (HCC).

Key Information:

Chemical Name: 1,1-Cyclopropanedicarboxamide, N-[4-[[7-[[1-(cyclopentylamino)cyclopropyl]methoxy]-6-methoxy-4-quinolinyl]oxy]-3-fluorophenyl]-N′-(4-fluorophenyl)-.
Purpose: Potential anti-cancer (antineoplastic) activity.

OriginatorAdvenchen Laboratories
DeveloperAdvenchen Laboratories; Chia Tai Tianqing Pharmaceutical Group
ClassAntineoplastics; Small molecules
Mechanism of ActionReceptor protein-tyrosine kinase antagonists
Phase IIINon-small cell lung cancer; Thyroid cancer
Phase IILung cancer; Ovarian cancer
Phase I/IIColorectal cancer; Neurofibromatosis 1; Pancreatic cancer
No development reportedSolid tumours
28 Oct 2025No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in China (PO, Capsule)
10 Oct 2025700363489: CTP push: KDM and HE updated
26 Aug 2025Chemical structure information added.

Vilzemetkib is an orally bioavailable small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration vilzemetkib targets and binds to the c-Met protein, prevents c-Met phosphorylation and disrupts c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.

SYN

[US20120123126]

https://patentscope.wipo.int/search/en/detail.jsf?docId=US73570351&_cid=P20-MJ6JF6-22611-1

EXAMPLE 6

N-(4-(7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-3-fluoro-phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

The title compound was prepared by similar manner to Example 3, by using cyclopentanone instead of tetrahydro-4H-pyran-4-one. Mass: (M+1), 643

SYN

WO-2022268158-A1

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022268158&_cid=P20-MJ6JJ7-25153-1

WO2012034055 discloses N-(4-((7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolone-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (hereinafter referred to as compound (I)) as a c-Met kinase inhibitor and its use in inhibiting tyrosine kinase activity. Compound (I) is a novel class of compounds with excellent pharmacological properties, capable of inhibiting the activity of various protein tyrosine kinases, such as c-Met, VEGFr, EGFr, c-kit, PDGF, FGF, SRC, Ron, Tie2, etc. This disclosure relates to the treatment of neurofibromatosis type I with compound (I).